Mutations in AML: Prognostic and therapeutic implications

Courtney D. Di Nardo, Jorge E. Cortes

Research output: Contribution to journalArticle

Abstract

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the proliferation and aberrant differentiation of immature clonal myeloid cells. The prognosis of AML is variable, based on clinical features such as patient age, performance status, and comorbidities, as well as leukemia-specific genetic features including cytogenetics and molecular classification. The modern application of next-generation sequencing technology has uncovered marked heterogeneity and genomic complexity within AML, based on the presence or absence of cooperating mutations within functional categories such as epigenetic regulators, cell signaling and proliferation pathways, and master hematopoietic transcription factors. Although the treatment of AML has hitherto changed little in the past 40 years, the enhanced scientific understanding of AML pathophysiology and leukemogenesis has led to the recent development of multiple targeted and selective treatment approaches, and our increasing awareness of functional AML subsets will be evermore used to inform rational and personalized treatment strategies.

Original languageEnglish (US)
Pages (from-to)348-355
Number of pages8
JournalHematology
Volume2016
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Mutation
Therapeutics
Hematologic Neoplasms
Myeloid Cells
Epigenomics
Cytogenetics
Comorbidity
Leukemia
Transcription Factors
Cell Proliferation
Technology

ASJC Scopus subject areas

  • Hematology

Cite this

Mutations in AML : Prognostic and therapeutic implications. / Di Nardo, Courtney D.; Cortes, Jorge E.

In: Hematology, Vol. 2016, No. 1, 01.01.2016, p. 348-355.

Research output: Contribution to journalArticle

Di Nardo, Courtney D. ; Cortes, Jorge E. / Mutations in AML : Prognostic and therapeutic implications. In: Hematology. 2016 ; Vol. 2016, No. 1. pp. 348-355.
@article{328be33548d04afebc12fb723290e243,
title = "Mutations in AML: Prognostic and therapeutic implications",
abstract = "Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the proliferation and aberrant differentiation of immature clonal myeloid cells. The prognosis of AML is variable, based on clinical features such as patient age, performance status, and comorbidities, as well as leukemia-specific genetic features including cytogenetics and molecular classification. The modern application of next-generation sequencing technology has uncovered marked heterogeneity and genomic complexity within AML, based on the presence or absence of cooperating mutations within functional categories such as epigenetic regulators, cell signaling and proliferation pathways, and master hematopoietic transcription factors. Although the treatment of AML has hitherto changed little in the past 40 years, the enhanced scientific understanding of AML pathophysiology and leukemogenesis has led to the recent development of multiple targeted and selective treatment approaches, and our increasing awareness of functional AML subsets will be evermore used to inform rational and personalized treatment strategies.",
author = "{Di Nardo}, {Courtney D.} and Cortes, {Jorge E.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1182/asheducation-2016.1.348",
language = "English (US)",
volume = "2016",
pages = "348--355",
journal = "Hematology",
issn = "1024-5340",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Mutations in AML

T2 - Prognostic and therapeutic implications

AU - Di Nardo, Courtney D.

AU - Cortes, Jorge E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the proliferation and aberrant differentiation of immature clonal myeloid cells. The prognosis of AML is variable, based on clinical features such as patient age, performance status, and comorbidities, as well as leukemia-specific genetic features including cytogenetics and molecular classification. The modern application of next-generation sequencing technology has uncovered marked heterogeneity and genomic complexity within AML, based on the presence or absence of cooperating mutations within functional categories such as epigenetic regulators, cell signaling and proliferation pathways, and master hematopoietic transcription factors. Although the treatment of AML has hitherto changed little in the past 40 years, the enhanced scientific understanding of AML pathophysiology and leukemogenesis has led to the recent development of multiple targeted and selective treatment approaches, and our increasing awareness of functional AML subsets will be evermore used to inform rational and personalized treatment strategies.

AB - Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the proliferation and aberrant differentiation of immature clonal myeloid cells. The prognosis of AML is variable, based on clinical features such as patient age, performance status, and comorbidities, as well as leukemia-specific genetic features including cytogenetics and molecular classification. The modern application of next-generation sequencing technology has uncovered marked heterogeneity and genomic complexity within AML, based on the presence or absence of cooperating mutations within functional categories such as epigenetic regulators, cell signaling and proliferation pathways, and master hematopoietic transcription factors. Although the treatment of AML has hitherto changed little in the past 40 years, the enhanced scientific understanding of AML pathophysiology and leukemogenesis has led to the recent development of multiple targeted and selective treatment approaches, and our increasing awareness of functional AML subsets will be evermore used to inform rational and personalized treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=85020374727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020374727&partnerID=8YFLogxK

U2 - 10.1182/asheducation-2016.1.348

DO - 10.1182/asheducation-2016.1.348

M3 - Article

C2 - 27913501

AN - SCOPUS:85020374727

VL - 2016

SP - 348

EP - 355

JO - Hematology

JF - Hematology

SN - 1024-5340

IS - 1

ER -